多囊卵巢综合征核心结局指标集发布前后的采用情况
本研究基于世界卫生组织国际临床试验注册平台,纳入2018年1月1日至2022年9月21日注册的395项多囊卵巢综合征临床试验,比较核心结局指标集(COS)于2020年2月4日发布前后的采用情况。结果显示,发布后通用域和体重指数的报告率分别从24.1%升至35.8%(P=0.011)和从17.8%升至26.5%(P=0.039),但整体采用程度未达预期。
要点
- COS发布后,通用域和体重指数的报告率显著上升。
- 395项试验中仅报告了33个核心结局中的26个和7个域中的5个。
- 生殖域及其生殖激素谱的采用率最高,分别为63.0%和38.7%。
核心结论
- COS发布两年后,其采用情况没有实质性改善,提示该COS可能需要进一步修订、细化和推广以提高PCOS研究的可比性。
研究设计与样本
- 基于临床试验注册平台的方法学研究,纳入2018年1月1日至2022年9月21日注册的395项符合条件的多囊卵巢综合征临床试验。
- 从世界卫生组织国际临床试验注册平台共检索到1258项注册临床研究,按纳入和排除标准筛选出395项,并根据COS发布日期(2020年2月4日)分为发布前和发布后两组。
主要发现
- 395项试验中报告了33个核心结局中的26个和7个域中的5个。
- 生殖域和生殖激素谱的采用率最高,分别为63.0%和38.7%。
- COS发布后,通用域的报告率从24.1%升至35.8%(P=0.011),体重指数的报告率从17.8%升至26.5%(P=0.039)。
- 通用域报告的核心结局总数达到统计学显著(P=0.012),多变量分析仍支持通用域的上述发现。
- 相关性分析显示大多数域之间正相关,但妊娠域与代谢域负相关。
关键数值与推荐
- COS on PCOS包含7个域共33个核心结局:通用域3个、代谢域8个、生殖域7个、妊娠域10个、心理域3个、肿瘤域1个、长期域1个。
临床怎么用
- 原文未据此给出推荐。
局限性
- 由于结局缺乏标准化定义,一致性评估过程中难以避免一定的主观性。
- 采用情况不理想的原因可能是核心结局缺乏具体定义,以及研究人员对该COS缺乏认识。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does the core outcome set (COS) on polycystic ovary syndrome (PCOS) impact the selection of research outcomes? SUMMARY ANSWER: Following the publication of the COS on PCOS, an increasing number of trials are reporting both the generic domain and body mass index; however, the uptake of this COS has not been as extensive as expected. WHAT IS KNOWN ALREADY: The COS on PCOS included 33 core outcomes in the following seven domains: the generic (3), metabolic (8), reproductive (7), pregnancy (10), psychological (3), oncological (1), and long-term (1). This was done to improve consistency in outcome selection and definition. However, thus far, no studies have investigated the effectiveness of this COS in the above-mentioned tasks. STUDY DESIGN, SIZE, DURATION: A methodological study based on the trial registries, including 395 eligible clinical trials registered between 1 January 2018 and 21 September 2022. PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 1258 registered clinical studies on PCOS were retrieved from the World Health Organization International Clinical Trials Registry Platform. Of those, 395 were selected according to the inclusion and exclusion criteria, and divided into two groups based on the publication date of the COS on PCOS (4 February 2020): pre-publication and post-publication. The practical uptake of this COS was explored after data collation, assessment, comparison of the uptake of core outcomes or domains before and after the publication of this COS, and correlation analysis between the domains. MAIN RESULTS AND THE ROLE OF CHANCE: There were 26 out of 33 core outcomes and five out of seven domains reported in the 395 trials. The highest uptake was observed for the reproductive domain and the reproductive hormonal profile (63.0% and 38.7%, respectively). After the publication of the COS on PCOS, the uptake of the generic domain and body mass index increased from 24.1% to 35.8% (P = 0.011) and 17.8% to 26.5% (P = 0.039), respectively. The total number of reported core outcomes in the generic domain met statistical significance (P = 0.012). Moreover, multivariable analyses still supported the above finding in the generic domain. Correlation analysis showed that most of the domains were positively correlated with each other. However, the pregnancy domain was negatively correlated with the metabolic domain. Reasons responsible for the unsatisfactory uptake may be the absence of specific definitions of core outcomes, as well as the lack of awareness among researchers regarding this COS. LIMITATIONS, REASONS FOR CAUTION: Due to the lack of standardized definition of outcomes, it was difficult to avoid some subjectivity in the process of consistency assessment. WIDER IMPLICATIONS OF THE FINDINGS: Two years after its publication, there was no substantial improvement in the uptake of the COS on PCOS. This suggests that this COS may require further revision, refinement, and promotion to improve the comparability of PCOS studies. STUDY FUNDING/COMPETING INTEREST(S): This work was funded by Beijing Municipal Health Science and Technology Achievements and Appropriate Technology Promotion Project (BHTPP2022069), and the special fund of Beijing Key Clinical Specialty Construction Project. The authors do not have conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.
引用
- Li W, Li G, Chi H, et al. Uptake of the core outcome set on polycystic ovary syndrome before and after its publication. Hum Reprod. 2023. PMID: 37533286. doi:10.1093/humrep/dead149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。